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were, furthermore, more sensitive to the presence of side effects than EQ-5D. 
 CONCLUSIONS: TooL is a novel system for measuring health utilities in patients 
with schizophrenia, schizoaffective disorder or bipolar depression that incorporates 
the patient perspective of side effects of antipsychotic treatment. Adverse effects from 
antipsychotic treatment impact the quality-of-life and should be taken into account in 
economic evaluations of treatments with different side effect proﬁles. TooL facilitates 
cost-utility analyses that reﬂect this important aspect of treatment choice and 
outcome.
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OBJECTIVES: To investigate the relationship of severity levels of anxiety identiﬁed 
by the GAD-7 scale and the degree of disability as assessed by other standard widely 
used questionnaires. METHODS: A random sample of 212 subjects was recruited in 
Mental Health and Primary Care centres; 50% diagnosed of Generalized Anxiety Dis-
order (GAD) by DSM-IV criteria, and the other 50% were concurrent matched con-
trols. In addition to the GAD-7, the following scales were also administered: Hamilton 
Anxiety scale (HAM-A), Hospital Anxiety and Depression Scale (HADS), and World 
Health Organization Disability Scale (WHO-DAS). The number of visits to primary 
care and specialized services were also measured. Correlations between scale scores 
were computed and also agreement between instrument-speciﬁc disability and severity 
levels. RESULTS: Strong and signiﬁcant (p  0.001) correlations were found between 
GAD-7 scores and other questionnaires: HAM-A (r  0.852), HADS-A (r  0.903), 
WHO-DAS (r  0.704). Although GAD-7 scores correlated with all WHO-DAS dimen-
sions, higher correlations were observed with Social Participation (r  0.741), Com-
prehension and Communication (r  0.679), and Labour (0.638) dimensions. Moderate 
but signiﬁcant correlations were also found between GAD-7 scores and the number 
of visits to Primary Care (r  0.393) and Specialized Services (r  0.373). HAM-A 
severity groups presented signiﬁcant differences in GAD-7 mean scores (F  205.3; 
df1  3; df2  208; p  0.001), and HAM severity groups also differed (F  175.3; 
df1  3; df2  208; p  0.001); in both cases all severity levels differed. CONCLU-
SIONS: The GAD-7 scale has shown to highly correlate not only with speciﬁc anxiety 
measures but also with disability measures. Not all WHO-DAS disability dimensions 
seem to be equally affected by GAD levels, and it has been shown that more 
severe GAD levels tend to demand more health attention. As the GAD-7 is self-admin-
istered and it is no time consuming, this instrument could be a good choice in primary 
care settings to explore the level of patient’s disability in subjects with GAD.
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BACKGROUND: IQWiG, the German health technology assessment agency, is 
required to focus on patient-relevant endpoints as part of their cost-beneﬁt analysis. 
Several patient preference studies conducted in Germany have identiﬁed “clear think-
ing” as a patient-relevant endpoint, but the measurement of this construct is limited 
by the absence of a conceptualization of clear thinking that is grounded in the patient 
experience. OBJECTIVES: To develop a conceptual model of clear thinking grounded 
in the experience of patients diagnosed with schizophrenia, aiding the creation of clear 
thinking scale. METHODS: A trained psychologist elicited deﬁnitions and examples 
of clear thinking from 25 German patients diagnosed with schizophrenia during open-
end, semi-structured interviews. Theory building was aided by literature review, 
including a review of existing scales of cognition, and an additional 15 depth inter-
views with patients and clinicians. Data was analyzed using a grounded theory 
approach, leading to multi-dimensional conceptualization of clear thinking. RESULTS: 
Clear thinking can be conceptualized by four themes: a) staying organized (including 
daily activities, making decisions and having organized thoughts); b) making sense of 
the world (identifying reality, verbal comprehension and visual comprehension); c) 
feeling clear headed (confusion, slowness and pacing); and d) expressing thoughts and 
feelings (feelings, communication and fullness of life). CONCLUSIONS: This concep-
tual model provides researchers and clinicians with a framework to consider clear 
thinking as deﬁned by patients diagnosed with schizophrenia. It will also provide the 
cornerstone for the development of a clear thinking scale to measure this patient-
 relevant endpoint and subsequently assess the validity of our conceptualization.
PMH61
PATIENTS PREFERENCES IN ADULTS WITH ADHD—A DISCRETE 
CHOICE EXPERIMENT
Mühlbacher AC1, Slawik L2, Kasper J3, Nübling M4
1Hochschule Neubrandenburg, Neubrandenburg, Germany, 2Janssen Cilag GmbH, Neuss, 
Germany, 3GEB: Gesellschaft für Empirische Beratung mbH—Empirical Consulting -, Freiburg, 
Germany, 4Gesellschaft für empirische Beratung mbH, D- 79211 Denzlingen, Germany
OBJECTIVES: For the majority of those concerned, ADHD is a lifelong chronic 
disease with prevalent underachievement in work life and impairments in social 
functioning. While clinical evidence on efﬁcacy and tolerability of treatment options 
for ADHD in adulthood is increasing, preferences of adults with ADHD have not yet 
been explored. Understanding their preferences contributes to present discussions in 
the health care sector on patients’ needs and shared decision-making. METHODS: An 
extended qualitative study (literature review, in-depth interviews and patient focus 
groups) was conducted in order to collect all relevant factors and success criteria for 
adults with ADHD (content validity). In the subsequent quantitative study, preferences 
for an ADHD treatment were investigated by using direct measurement (rating 23 
aspects on a ﬁve point Likert-scale) as well as a Discrete-Choice-Experiment (DCE) 
with 8 pairs of treatment options described by 6 dichotomous parameters. RESULTS: 
14 in-depth interviews and ﬁve focus groups with 4–12 adult participants each (n  
35) were conducted. 329 persons (18- 65 years, 63%female) ﬁlled the questionnaire 
of the quantitative study (89% online, 11% paper&pencil). In the direct assessment, 
“long-term positive effects (e.g. behaviour changes)”, “improved ability to concen-
trate”, “allows “normal” daily living” and “improves emotional stability” reached 
the highest values (means around 90). In the DCE (random effects logit model) “social 
abilities (profession, friendship possible)” had the highest impact on choices (coefﬁ-
cient 2.12) followed by “long-term behaviour changes” (1.75), “fast symptom relief” 
(1.10), “no impact on positive ADHD traits” (1.04), and “emotional stability (no 
mood swings)” (0.81). These factors were highly signiﬁcant (p  0.001) while “neces-
sity of medical treatment” had no signiﬁcant inﬂuence. CONCLUSIONS: The pre-
sented study systematically explored patient preferences and hereby contributes to a 
better understanding of the medical needs of adults diagnosed with ADHD. The 
achievement of social abilities and long lasting behavioural effects attributed greatest 
beneﬁt to the respondents.
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OBJECTIVES: To develop a cross-cultural adaptation from Swedish into Spanish of 
the TooL questionnaire—a previously validated instrument to assess side effects’ 
impact on HRQoL in patients with schizophrenia and bipolar disorder. METHODS: 
An epidemiological multicentre, cross-sectional study was carried out to analyze the 
psychometric properties of the Spanish TooL. It comprises 8 attributes and 4 levels 
per domain (Likert scale: 1-minimun impact; 4-maximun impact): worry-upset, func-
tion capabilities, fatigue-weakness, weight gain, stiffness-tremor, physical restlessness, 
sexual dysfunction, and dizziness-nausea. Patients completed both generic and speciﬁc 
measures of HRQoL and severity (EQ-5D and SF6D –unweighted- and the Clinical 
Global Impression -CGI-SI-, UKU side effects rating scale, Positive and Negative Syn-
drome scale, Young Mania Rating Scale, Montgomery Adsberg Depression Rating 
Scale). Reliability (Cronbach’s A and intraclass correlation coefﬁcient –ICC-), con-
struct validity (factorial analysis –FA- and item-total correlations -ITC), convergent 
validity (Spearman’s rank correlations between measures –rs-) and criterion validity 
(Mann-Whitney U differences between mild vs moderate-severe patients according to 
CGI-SI) were evaluated. RESULTS: A total of 242 patients were included (121 with 
schizophrenia and 121 with bipolar disorder). Internal consistency and ICC were 
adequate (Cronbach’s A  0.757 & ICC  0.90). FA and ITC showed that one-
 dimensional structure could be assumed (1 eigenvalue 1 and 40% of variance 
explained). Correlations (rs) between the Spanish TooL and both generic and speciﬁc 
measures were moderate-high. Differences in the Spanish TooL scores between mild 
vs moderate-severe patients were highlighted. CONCLUSIONS: The Swedish TooL 
questionaire was culturally adapted and validated into Spanish. Further investigation 
is needed to test the sensitivity of the Spanish TooL questionnaire.
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OBJECTIVES: To estimate and assess the psychometric properties of a Multi-Attribute 
Utility Function for the Spanish version of the TOOL questionnaire (TOOL MAUF). 
TOOL is a recently developed 8-item (4-level) instrument measuring antipsychotics 
side effects´ impact on health status. METHODS: Balanced data on 242 patients 
diagnosed with schizophrenic or bipolar disorders were gathered. In addition to 
demographic and clinical variables, and the usual generic HRQoL questionnaires, 
EQ5D and SF6D, instruments considered included the Spanish versions of the Positive 
and Negative Syndrome Scale (PANSS), Young Mania Rating Scale (YMRS), Mont-
gomery-Asberg Depression Rating Scale (MADRS), UKU side effect rating scale, and 
TOOL questionnaire. TOOL MAUF parameters estimation involved a number of VAS 
and TTO ratings of different health states deﬁned from TOOL items. Such ratings 
proved hard to be performed by patients. After checking for inconsistencies in patient 
responses (missing data, out-of-range responses, and rating reversals), the original 
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sample was reduced to a still balanced subsample of 70 patients. VAS ratings were 
transformed into utilities by specifying a power function. A multiplicative-form MAUF 
was estimated following the standard methodology. RESULTS: Individual utilities 
from TOOL MAUF showed adequate unbiased predictive validity. Good convergent 
validity was evidenced, since estimated utilities presented strong correlations with 
utilities from generic HRQoL instruments: SF6D (0.664, p  0.001), EQ5D (0.690, p 
 0.001)); and moderate correlations with the rest of instruments included: PANSS 
(0.275, p  0.100), YMRS (0.296, p  0.080), MADRS (0.483, p  0.001), UKU 
(0.424, p  0.002). Criterion validity was also met, as differences in mean utilities 
by clinical severity were found (p  0.008). Interestingly, utilities from TOOL MAUF 
covered a wider range of health states (0.037, 1.000) than those from SF6D and EQ5D 
(0.233, 0.960), since TOOL is a speciﬁc instrument. CONCLUSIONS: Utilities from 
TOOL MAUF show good psychometric properties and cover a wider range of health 
states than utilities from other generic HRQoL instruments.
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OBJECTIVES: The purpose of this study was to describe the current situation of Post 
Traumatic Stress Disorder (PTSD) among Hungarian prehospital ambulance staff and 
make suggestions for the workplace. METHODS: In the study we involved 60 persons 
at ﬁve ambulance station in Pest county randomly. Standardized self-ﬁll-in PTSD and 
burn out questionnaire were used in an interview process to collect information. The 
items included PTSD symptoms, coping mechanisms, social support and burn out. 
Data collection was carried out in 2008 and statistical analysis as one-way analysis 
of variance (ANOVA) was performed with SPSS 14.0. RESULTS: All respondents 
were male with an average age 33,2 years. More than two third (66.7%) of all people 
spent 1–5 years with ambulance service. Eightoeen out of 60 suffer on a chronic condi-
tion, mainly in locomotion system. The PTSD symptoms are present in 17 (28.3%) 
ambulance man and they can get support from colleagues (75%), family (66.7%) and 
friends (58.35) and very rearly from professionals, like psychologist (6.7%). The 
respondents indicated “No one would help” in 8,3%. Regarding to burn out: 15% is 
in danger, in 5% in burnt out. The half of the respondents are at risk of symptoms 
of burn out. The symptoms of PTSD and burn out correlated with no active sport 
(p  0.05), with a second job (p  0.05) and poor working conditions (p  0.05). 
CONCLUSIONS: The results showed a high percentage of PTSD symptoms and 
risk of burn out which needs already treatment. Health promotion at work place, 
coaching techniques and a pschychologist at work place can provide a better outcome 
for ambulance personnel.
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OBJECTIVES: To evaluate in a cohort of depressed patients if response within the 
ﬁrst 6 weeks of antidepressant treatment (AD) is associated with a change in health-
related quality of life (HRQoL) after 1-year follow-up. METHODS: This is a 1-year, 
longitudinal, prospective and multicenter study of a cohort of outpatients with major 
depression. Main objective was to assess the predictive value of early antidepressant 
response in long-term good outcome. Patients were included when they started an AD 
for index episode. Early response was deﬁned as a 50% improvement on the 17-Item 
Hamilton Depression Rating Scale total score (HAM-D17) within the ﬁrst 6 weeks, 
and good outcome when the patient achieved remission (HAM-D17 a7) in the ﬁrst 6 
months and remained in remission until end of follow-up. HRQoL was scored by the 
European Quality of Life-5 Dimensions (EQ-5D). The change of the scoring from 
baseline to end of follow-up in the EuroQol was analyzed by means of an ANCOVA 
model. RESULTS: 930 patients were included in the study. At baseline, mean age was 
47.1 years (SD, 13.5), 67.9% were female and mean HAM-D17 score was 24.2 (SD, 
5.5). 355 patients (38.2%) showed early response and of those 76.1% had a good 
outcome, versus 43% of those patients without early response. The baseline EQ-5D 
index raw scores (95% Conﬁdence interval, CI) improved from 0.25 (0.22–0.29) to 
0.91 (0.89–0.93) among patients who showed early response, and from 0.23 (0.21–
0.26) to 0.81 (0.79–0.83) among those without it. Improvement in EQ-5D scores was 
associated with early response, gender, having lower baseline HRQoL (EQ-5D), higher 
depressive scores (HAM-D17) and higher level of anxiety (HAM-A). Moreover there 
were interactions found between gender and early response. CONCLUSIONS: 
Depressed patients experienced improvements in HRQoL after starting AD. This 
improvement was associated with early antidepressant response.
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OBJECTIVES: Olanzapine Long-Acting Injection (OLAI) was developed to provide 
individuals with schizophrenia, particularly those who struggle with adherence, with 
an effective and convenient alternative to oral antipsychotics. The present study com-
pared quality of life and patient-reported outcomes between oral and long-acting 
injectable formulations of olanzapine in the treatment of schizophrenia. METHODS: 
Clinician-rated quality of life and patient-reported outcomes were evaluated in a 24-
week double-blind, randomized clinical trial comparing OLAI with oral olanzapine in 
clinically stabilized individuals with schizophrenia. The measures used included the 
Heinrichs-Carpenter Quality of Life Scale (QLS), the Short Form Health Survey (SF-
36), and the Drug Attitude Inventory (DAI). RESULTS: Of the 1065 randomized 
individuals, the majority were male (65.4%) and Caucasian (71.8%), with a mean 
age of 39 years and a baseline PANSS Total score of 55.9 (SD  15.6). In general 
changes in QLS, SF-36, and DAI for individuals on OLAI were similar to those for 
individuals receiving oral olanzapine with the exception of statistically signiﬁcant dif-
ferences on some SF-36 subscales. However these differences across treatment groups 
were not considered clinically meaningful. Despite examination in a symptomatically 
stable population, signiﬁcant improvements in quality of life as measured by the QLS 
total scores were seen in the group taking OLAI for two of the three therapeutic doses 
(405 mg/4 wk, p  0.001 and 300 mg/2 wk, p  0.003) and the group taking oral 
olanzapine (p  0.001). There were no signiﬁcant differences in QLS across treatment 
groups. CONCLUSIONS: Subjects remained stable over the course of the study, and 
many experienced an increase in quality of life regardless of assignment to OLAI or 
oral olanzapine. The ﬁndings suggest symptomatically stable individuals receiving 
OLAI will maintain health outcomes comparable with those taking oral olanzapine. 
OLAI may be useful for individuals who desire the effectiveness of olanzapine without 
requiring daily dosing.
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OBJECTIVES: To investigate the health status and quality of life of demented patients 
in Hungary, examining the correlation between disease characteristics and quality of 
life (QoL). Also to compare QoL results of the demented patients with the general 
Hungarian population’s scores by age-groups. METHODS: A cross-sectional study of 
88 consecutive patients was conducted in 2008 involving 3 GP and 1 outpatient set-
tings. Investigating the health related quality of life, EuroQoL (EQ-5D) questionnaire 
was applied and completed by assistants’ guidance. Mini-Mental State Examination 
(MMSE) and Resource Utilization in Dementia (RUD) questionnaire were completed 
as well. Negatives EQ-5D scores were replaced by 0. Spearman correlation coefﬁcients 
were performed. RESULTS: Eighty-eight patients (59% female) were involved in the 
survey with mean age of 78 years (SD 8.5) and average disease duration of 4.3 years 
(SD 5.1). Mean MMSE was 16.7 (SD 7.24) and EQ-5D score was 0.401 (SD 0.327). 
Average EQ-5D values of the general Hungarian population aged 65–74, 75–85 and 
85 years were 0.756, 0.634 and 0.629, respectively, whilst these values were 0.530, 
0.424 and 0.220 in our sample. Signiﬁcant correlation was observed between EQ-5D 
score and disease duration, MMSE score, and the time-resource utilization (physical 
and instrumental activities of daily living as well as supervision hours), at p  0.01. 
For mild (MMSE 18–23), moderate (MMSE 10–17) and severe (MMSE 0–9) dementia 
the EQ-5D values decreased by disease severity, with mean values of 0.56 (SD. 0.28), 
0.29 (SD. 0.32) and 0.19 (SD. 0.31), respectively. Although for mild cognitive impair-
ment (MMSE 24–30) it resulted in lower values than in mild dementia, with mean 
0.53 (SD. 0.33) CONCLUSIONS: Dementia causes a signiﬁcant decline in the quality 
of life, diminishing EQ-5D values by disease severity. EQ-5D values are remarkably 
lower in all age groups among demented people compared to general population.
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OBJECTIVES: While the effects of dementia on patients are well documented, aware-
ness of its negative impact on the life of caregivers needs to be increased. The objective 
of this survey was to provide data from physicians and caregivers on the impact of 
dementia on both patients and carers. METHODS: Adelphi’s Dementia Disease Spe-
ciﬁc Programme is an independent real world observational survey of cognitively 
impaired patients aged over 50 managed by primary or secondary care physicians in 
ﬁve European countries during 2008. Information from non-professional caregivers 
was collected using a prospective questionnaire including details of employment status, 
patient accommodation, patient’s current symptoms, patient compliance with treat-
ment and the carer’s quality of life measured by a validated instrument (Zarit Care-
giver Burden Interview). RESULTS: The caregiver questionnaires (n  847) showed 
